A larger body doesn’t necessarily mean you have ‘clinical obesity’, according to a proposed new definition of the disease.

There's no doubt that self-injection devices have transformed the lives of people with chronic diseases like diabetes ... according to Novo Nordisk. "Up to 85% of the materials in every pen ...

While the attention of late has been firmly focused on Novo Nordisk's obesity and diabetes business ... designed by reusing excess soil, wooden materials and other sustainable resources ...

Stocks are pricey—but there are values to be had. Learn more about our panelists’ picks in this week’s Roundtable installment.

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY and Novo Nordisk NVO stock. As the major players in the hyper-scale ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...